Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: A retrospective study

Drugs and Aging

Volumn 30, Issue 8, 2013, Pages 629-637

  Latagliata, Roberto ^a   Ferrero, Dario ^b   Iurlo, Alessandra ^c   Cavazzini, Francesco ^d   Castagnetti, Fausto ^e   Abruzzese, Elisabetta ^f   Fava, Carmen ^g   Breccia, Massimo ^a   Annunziata, Mario ^h   Stagno, Fabio ⁱ   Tiribelli, Mario ^j   Binotto, Gianni ^k   Mansueto, Giovanna ^l   Gozzini, Antonella ^m   Russo, Sabina ⁿ   Cavalli, Laura ^o   Montefusco, Enrico ^p   Gugliotta, Gabriele ^e   Cedrone, Michele ^q   Russo Rossi, Antonella ^r   Avanzini, Paolo ^s   Pregno, Patrizia ^t   Mauro, Endri ^u   Spadea, Antonio ^v   Celesti, Francesca ^w   Giglio, Gianfranco ^x   Isidori, Alessandro ^y   Crugnola, Monica ^z   Calistri, Elisabetta ^aa   Sorà, Federica ^ab   Storti, Stefano ^ac   D'Addosio, Ada ^ad   Rege Cambrin, Giovanna ^g   Luciano, Luigiana ^ae   Alimena, Giuliana ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f S EUGENIO HOSPITAL   (Italy)

^g Ematologia Polo Universitario ASO San Luigi Gonzaga   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ Ospedale Ferrarotto   (Italy)

^j UNIVERSITY OF UDINE   (Italy)

^k UNIVERSITY OF PADOVA   (Italy)

^l REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ UNIVERSITY OF MESSINA   (Italy)

^o UNIVERSITY OF PERUGIA   (Italy)

^p SAPIENZA UNIVERSITY OF ROME   (Italy)

^q SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^r UNIVERSITY OF BARI   (Italy)

^s Ematologia   (Italy)

^t MOLINETTE HOSPITAL   (Italy)

^u S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^v REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^w BELCOLLE HOSPITAL   (Italy)

^x Università del MoliseCampobasso   (Italy)

^y Ematologia   (Italy)

^z UNIVERSITY OF PARMA   (Italy)

^aa OSPEDALE CA FONCELLO   (Italy)

^ab CATHOLIC UNIVERSITY   (Italy)

^ac CATHOLIC UNIVERSITY   (Italy)

^ad Ospedale Villa S Pietro   (Italy)

^ae UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ACUTE HEART INFARCTION; AGED; ANEMIA; ARTICLE; BONE PAIN; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; HUMAN; ITALY; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; MUSCLE CRAMP; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; BENZAMIDES; COHORT STUDIES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; ITALY; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; NEOPLASM GRADING; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84880850549     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0088-6     Document Type: Article

References (21)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-7.
2. Druker BJ, Guilhot F, O'Brien SG, IRIS Investigators, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
3. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood. 2008;111:1039-43.
4. Björkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514-20.
5. Cortes J, Talpaz M, O'Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98:1105-13.
6. Latagliata R, Breccia M, Carmosino I, et al. Older patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res. 2005;29:287-91.
7. Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007;92:101-5.
8. Sheehy OM, Irvine AE, Cuthbert RJ, et al. Use of imatinib mesylate in older patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients. Hematology. 2008;13:133-6.
9. Latagliata R, Breccia M, Carmosino I, et al. "Real-life" results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34:1472-5.
10. Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117:5591-9.
11. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686-9.
12. Champion KM, Gilbert JG, Asimakopoulos FA, et al. Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol. 1997;97:920-6.
13. Rohrbacher M, Berger U, Hochhaus A, et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia. 2009;23:602-4.
14. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
15. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112:3330-8.
16. Muller MC, Erben P, Saglio G, et al. European LeukemiaNet. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22:96-102.
17. Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: Changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 2009;127:1-4.
18. Bonifazi F, De Vivo A, Rosti G, et al. Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. Br J Haematol. 2000;111:587-95.
19. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850-8.
20. Ohnishi K, Nakaseko C, Takeuchi J, et al. Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci. 2012;103:1071-8.
21. Latagliata R, Breccia M, Castagnetti F, et al. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leuk Res. 2011;35:1164-9.